Potential new anticancer molecular targets for the treatment of human testicular seminomas

Mini-Reviews in Medicinal Chemistry

Volumn 11, Issue 12, 2011, Pages 1075-1081

  Chieffi, P ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Gonocytes; Seminomas; Testicular cancer; Testicular germ cells; Testis

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AURORA A KINASE; AURORA B KINASE; BARASERTIB; BEVACIZUMAB; G PROTEIN COUPLED RECEPTOR 30; HESPERADIN; HIGH MOBILITY GROUP A2 PROTEIN; IMATINIB; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; OCTAMER TRANSCRIPTION FACTOR 4; PATZ1 PROTEIN; PESTICIDE; STEM CELL FACTOR RECEPTOR; THROMBOSPONDIN 1; TOZASERTIB; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; VANDETANIB; ZINC FINGER PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BODY MASS; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL FUNCTION; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DIET; DISEASE PREDISPOSITION; EMBRYONAL CARCINOMA; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; GENETIC LINKAGE; GENOMIC INSTABILITY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; MATERNAL SMOKING; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; RISK FACTOR; SEMINOMA; TERATOCARCINOMA;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; SEMINOMA; STRUCTURE-ACTIVITY RELATIONSHIP; TESTICULAR NEOPLASMS;

EID: 80054856853     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955711797247770     Document Type: Review

References (83)

1. Chieffi, P. Molecular targets for the treatment of testicular germcell tumors. Mini Rev. Med. Chem., 2007, 7, 755-9.
2. Chieffi P.; Franco, R.; Portella G. Molecular and cell biology oftesticular germ cell tumors. Int. Rev. Cell Mol. Biol., 2009, 278, 277-308.
3. Oosterhuis, J.W.; Looijenga, L.H. Testicular germ-cell tumors in abroader perspective. Nat. Rev. Cancer 2005, 5, 210-22.
4. Ulbright, T.M. Germ cell neoplasm of the testis. Am. J. Surg. Pathol., 1993, 17, 1075-91.
5. Chaganti, R.S.; Houldsworth, J. Genetics and biology of adulthuman male germ cell tumors. Cancer Res., 2000, 60, 1474-82.
6. Jones, R.H.; Vasey, P.A. Part II: testicular cancer-management ofadvanced disease. Lancet Oncol., 2003, 4, 738-47.
7. Shelley, M.D.; Burgon, K.; Mason, M.D. Treatment of testiculargerm-cell cancer: a cochrane evidence-based systematic review. Cancer Treat. Rev., 2002, 28, 237-53.
8. Al Ghamdi, A.M.; Jewett, M.A. Stage I nonseminomatous germcell tumours: the case for management by risk stratification. Can. J. Urol., 2005, 12, 62-5.
9. Classen, J.; Souchon, R.; Hehr, T.; Bamberg, M. Treatment of earlystage testicular seminoma. J. Cancer Res. Clin. Oncol., 2001, 127, 475-81.
10. Perrotti, M.; Ankem, M.; Bancilla, A.; deCarvalho, V.; Amenta, P.;Weiss, R. Prospective metastatic risk assignment in clinical stage Inonseminomatous germ cell testis cancer: a single institution pilotstudy. Urol. Oncol., 2004, 22, 174-7.
11. Bonner, M.R.; McCann, S.E.; Moysich, K.B. Dietary factors andthe risk of testicular cancer. Nutr. Cancer, 2002, 44, 35-43.
12. Dieckmann, K.P.; Pichlmeier, U. Is risk of testicular cancer relatedto body size? Eur. Urol., 2002, 42, 564-9.
13. Dieckmann, K.P.; Hartmann, J.T.; Classen, J.; Lüdde, R.;Diederichs, M.; Pichlmeier, U. Tallness is associated with risk oftesticular cancer: evidence for the nutrition hypothesis. Br. J. Cancer, 2008, 99, 1517-21
14. Dieckmann, K.P.; Hartmann, J.T.; Classen, J.; Diederichs, M.;Pichlmeier, U. Is increased body mass index associated with theincidence of testicular germ cell cancer? J. Cancer Res. Clin. Oncol., 2009, 135, 731-8.
15. Garner, M.J.; Birkett, N.J.; Johnson, K.C.; Shatenstein, B.;Ghadirian, P.; Krewski, D.; Canadian Cancer RegistriesEpidemiology Research Group Dietary risk factors for testicularcarcinoma. Int. J. Cancer, 2003, 106, 934-41.
16. McGlynn, K.A.; Quraishi, S.M.; Graubard, B.I.; Weber, J.P.;Rubertone, M.V.; Erickson, R.L.; Persistent organochlorinepesticides and risk of testicular germ cell tumors. J. Natl. CancerInst., 2008, 100, 663-71.
17. Martin, O.V.; Shialis, T.; Lester, J.N.; Scrimshaw, M.D.; Boobis, A.R.; Voulvoulis, N. Testicular dysgenesis syndrome and theestrogen hypothesis: a quantitative metaanalysis. Environ. HealthPerspect, 2008, 116, 149-57.
18. Garner, M.; Turner, M.C.; Ghadirian, P.; Krewski, D.; Wade, M. Testicular cancer and hormonally active agents. J. Toxicol. Environ. Health B Crit. Rev., 2008, 11, 260-75.
19. Strohsnitter, W.C.; Noller, K.L.; Hoover, R.N.; Robboy, S.J.;Palmer, J.R.; Titus-Ernstoff, L.; Kaufman, R.H.; Adam, E.; Herbst, A. L; Hatch, E.E. Cancer risk in men exposed in utero todiethylstilbestrol. J. Natl. Cancer Inst., 2001, 93, 545-51.
20. Dieckmann, K.P.; Endsin, G.; Pichlmeier, U. How valid is theprenatal estrogen excess hypothesis of testicular germ cell cancer?A case control study on hormone-related factors. Eur. Urol., 2001, 40, 677-83.
21. Ekbom, A.; Richiardi, L.; Akre, O.; Montgomery, S.M.; Sparen, P. Age at immigration and duration of stay in relation to risk fortesticular cancer among Finnish immigrants in Sweden. J. Natl. Cancer Inst., 2003 95, 1238-40.
22. Montgomery, S.M.; Granath, F.; Ehlin, A.; Sparen, P.; Ekbom, A. Germ-cell testicular cancer in offspring of Finnish immigrants toSweden. Cancer Epidemiol. Biomarkers Prev., 2005, 14, 280-2.
23. Forman, D.; Oliver, R.T.; Brett, A.R.; Marsh, S.G.; Moses, J.H.;Bodmer, J.G.; Chilvers, C.E.; Pike, M.C. Familial testicular cancer:a report of the UK family register, estimation of risk and an HLAclass 1 sib-pair analysis. Br. J. Cancer, 1992, 65, 255-62.
24. Lutke Holzik, M.F.; Rapley, E.A.; Hoekstra, H.J.; Sleijfer, D.T.;Nolte, I.M.; Sijmons, R.H. Genetic predisposition to testiculargerm-cell tumours. Lancet Oncol., 2004, 5, 363-71.
25. Skakkebaek, N.E. Possible carcinoma-in-situ of the testis. Lancet, 1972, 2, 516-7.
26. Wicha, M.S.; Liu, S.; Dontu, G. Cancer stem cells: an old idea-aparadigm shift. Cancer Res., 2006, 66, 1883-90.
27. Ulbright, T.M. Protocol for the examination of specimens frompatients with malignant germ cell and sex cord-stromal tumors ofthe testis, exclusive of paratesticular malignancies: a basis forchecklists. Arch. Pathol. Lab. Med., 1999, 123, 14-9.
28. Berthelsen, J.G.; Skakkebaek, N.E.; von der Maase, H.; Sorensen, B.L.; Mogensen, P. Screening for carcinoma in situ of thecontralateral testis in patients with germinal testicular cancer. Br. Med. J., 1982, 285, 1683-6.
29. Nielsen, H.; Nielsen, M.; Skakkebaek, N.E. The fine structure ofpossible carcinoma in-situ in the seminiferous tubules in the testisof four infertile men. Acta Pathol. Microbiol. Scand. A., 1974, 82, 235-48.
30. Skakkebaek, N.E.; Berthelsen, J.G.; Giwercman, A.; Müller, J. Carcinoma-in-situ of the testis: possible origin from gonocytes andprecursor of all types of germ cell tumours except spermatocytoma. Int. J. Androl., 1987, 10, 19-28.
31. Muller, J.; Skakkebaek, N.E.; Nielsen, O.H.; Graem, N. Cryptorchidism and testis cancer. Atypical infantile germ cellsfollowed by carcinoma in situ and invasive carcinoma in adulthood. Cancer, 1984, 54, 629-34.
32. Almstrup, K.; Hoei-Hansen, C.E.; Wirkner, U.; Blake, J.;Schwager, C.; Ansorge, W.; Nielsen J.E.; Skakkebaek, N.E.;Rajpert-De Meyts, E.; Leffers, H. Embryonic stem cell-likefeatures of testicular carcinoma in situ revealed by genome-widegene expression profiling. Cancer Res., 2004, 64, 4736-43.
33. Hoei-Hansen, C.E.; Almstrup, K.; Nielsen, J.E.; Brask Sonne, S.;Graem, N.; Skakkebaek, N.E.; Leffers H.; Rajpert-De Meyts, E. Stem cell pluripotency factor NANOG is expressed inhuman fetalgonocytes, testicular carcinoma in situ and germ cell tumours. Histopathol., 2005, 47, 48-56.
34. Looijenga, L.H. Human testicular (non)seminomatous germ celltumours: the clinical implications of recent pathobiologicalinsights. J. Pathol., 2009, 218, 146-62.
35. Rajpert-De Meyts, E.; Bartkova, J.; Samson, M.; Hoei-Hansen, C.E.; Frydelund-Larsen, L.; Bartek, N.E.; Skakkebaek, N.E. Theemerging phenotype of the testicular carcinoma in situ germ cell. APMIS, 2003, 111, 267-78.
36. Chieffi, P.; Battista, S.; Barchi, M.; Di Agostino, S.; Pierantoni, G.;Fedele, M.; Chiariotti, L.; Tramontano, D.; Fusco, A. HMGA1 andHMGA2 protein expression in mouse spermatogenesis. Oncogene, 2002, 21, 3644-50.
37. Franco, R.; Esposito, F.; Fedele, M.; Liguori, G.; Pierantoni, G.;Botti, G.; Tramontano D.; Fusco A.; Chieffi P. Detection of highmobility group proteins A1 and A2 represents a valid diagnosticmarker in post-puberal testicular germ cell tumours. J. Pathol., 2008, 214, 58-64.
38. Fedele, M.; Franco, R.; Salvatore, G.; Baronetto, M.P.; Barbagallo, F.; Pero, R.; Chiariotti L.; Sette C.; Tramontano D.; Chieffi G.;Fusco A.; Chieffi, P. PATZ1 gene has a critical role in thespermatogenesis and testicular tumours. J. Pathol., 2008, 215, 39-47.
39. Esposito, F.; Boscia, F.; Franco, R.; Tornincasa, M.; Fusco, A.;Kitazawa, S.; Looijenga, L.H.; Chieffi, P. Down-regulation ofestrogen receptor-α associates with transcriptional coregulatorPATZ1 delocalization in human testicular seminomas. J. Pathol., 2011, 224. 110-120.
40. Chieffi, P.; Troncone, G.; Caleo, A.; Libertini, S.; Linardopoulos, S.; Tramontano, D.; Portella G. Aurora B expression in normaltestis and seminomas. J. Endocrinol., 2004, 181, 263-70.
41. Esposito, F.; Libertini, S.; Franco, R.; Abagnale, A.; Marra, L.;Portella, G.; Chieffi P. Aurora B expression in post-puberaltesticular germ cell tumours. J. Cell. Physiol., 2009, 221, 435-9.
42. Barbagallo, F.; Baronetto, M.P.; Franco, R.; Chieffi, P.; Dolci, S.;Fry, A.M.; Geremia R.; Sette C. Increased expression and nuclearlocalization of the centrosomal kinase Nek2 in human testicularseminomas. J. Pathol., 2009, 217, 431-41.
43. de Jong, J.; Stoop, H.; Dohle, G.R.; Bangma, C.H.; Kliffen, M.; van Esser, J.W.; van den Bent M.; Kros, J.M.; Oosterhuis, J.W.;Looijenga, L.H. Diagniostic value of OCT3/4 for pre-invasive andinvasive testicular germ cell tumours. J. Pathol., 2005, 206, 242-9.
44. Looijenga, L.H.; Stoop, H.; de Leeuw, H.P.; de Gouveia Brazao, C.A.; Gillis, A.J.; van Roozendaal, K.E.; van Zoelen, E.J.; Weber, R.F.; Wolffenbuttel, K.P.; van Dekken, H.; Honecker, F.;Bokemeyer, C.; Perlman, E.J.; Schneider, D.T.; Kononen, J.;Sauter, G.; Oosterhuis, J, W. POU5F1 (OCT3/4) identifies cellswith pluripotent potential in human germ cell tumors. Cancer Res., 2003, 63, 2244-50.
45. Atlasi, Y.; Mowla, S.J.; Ziaee, S.A.; Gokhale, P.J.; Andrews, P.W. OCT4 spliced variants are differentially expressed in humanpluripotent and non-pluripotent cells. Stem Cells, 2008, 26, 3068-74.
46. Ledford, H. Doubts raised over stem-cell marker. Nature (London)2007, 449, 647.
47. Lengner, C.J.; Camargo, F.D.; Hochedlinger, K.; Welstead, G.G.;Zaidi, S.; Gokhale, S. Oct4 expression is not required for mousesomatic stem cell self-renewal. Cell Stem Cell, 2007, 1, 403-15.
48. Liedtke, S.; Enczmann, J.; Waclawczyk, S.; Wernet, P.; Kogler, G. Oct4 and its pseudogenes confuse stem cell research. Cell StemCell, 2007, 1, 364-6.
49. de Jong, J.; Looijenga, L.H. Stem cell marker OCT3/4 in tumorbiology and germ cell tumor diagnostics: history and future. Crit. Rev. Oncog., 2006, 12, 171-203.
50. Avilion, A.A.; Nicolis, S.K.; Pevny, L.H.; Perez, L.; Vivian, N.;Lovell Badge, R. Multipotent cell lineages in early mousedevelopment depend on SOX2 function. Genes Dev., 2003, 17, 126-40.
51. Boiani, M.; Scholer, H.R. Regulatory networks in embryo-derivedpluripotent stem cells. Nat. Rev. Mol. Cell Biol., 2005, 6, 872-84.
52. Yamaguchi, S.; Kimura, H.; Tada, M.; Nakatsuji, N.; Tada, T. Nanog expression in mouse germ cell development. Gene Expr. Patterns, 5, 639-646.
53. Yates, A., Chambers, I., 2005. The homeodomain protein Nanogand pluripotency in mouse embryonic stem cells. Biochem. Soc. Trans., 2005, 33(Part 6), 1518-21.
54. Hart, A.H.; Hartley, L.; Parker, K.; Ibrahim, M.; Looijenga, L.H.;Pauchnik, M.; Chow, C.W.; Robb, L. The pluripotency homeoboxgene NANOG is expressed in human germ cell tumors. Cancer, 2005, 104, 2092-8.
55. de Jong, J.; Stoop, H.; Gillis, A.J.; van Gurp, R.J.; van de Geijn, G.J.; Boer, M.; Hersmus, R.; Saunders, P.T.; Anderson, R.A.;Oosterhuis, J.W.; Looijenga, L.H. Differential expression ofSOX17 and SOX2 in germ cells and stem cells has biological andclinical implications. J. Pathol., 2008, 215, 21-30.
56. Korkola, J.E.; Heck, S.; Olshen, A.B.; Reuter, V.E.; Bosl, G.J.;Houldsworth, J.; Chaganti, R.S. In vivo differentiation and genomicevolution in adult male germ cell tumors. Genes ChromosomesCancer, 2008, 47, 43-55.
57. Kim, I.; Saunders, T.L.; Morrison, S.J. Sox17 dependencedistinguishes the transcriptional regulation of fetal from adulthematopoietic stem cells. Cell, 2007, 130, 470-83.
58. Gashaw, I.; Grummer, R.; Klein-Hitpass, L.; Dushaj, O.;Bergmann, M.; Brehm, R.; Grobholz, R.; Kliesch, S.; Neuvians, T.P.; Schmid, K.W.; von Ostau, C.; Winterhager, E. Genesignatures of testicular seminoma with emphasis on expression ofets variant gene 4. Cell. Mol. Life Sci., 2005, 62, 2359-68.
59. Gashaw, I.; Dushaj, O.; Behr, R.; Biermann, K.; Brehm, R.;Rübben, H.; Grobholz R; Schmid, K.W.; Bergmann, M.;Winterhager, E. Novel germ cell markers characterize testicularseminoma and fetal testis. Mol. Hum. Reprod., 2007, 13, 721-7.
60. Staibano, S.; Franco, R.; Mezza, E.; Chieffi, P.; Sinisi, A.;Pasquali, D.; Errico, M.E.; Nappi, C.; Tremolaterra, F.; Somma, P.;Mansueto, G.; De Rosa G. Oestrogen receptor Beta, PCNA, P53, and DNA ploidy: are they markers of biological behavior inovarian granulosa cell tumours? Histopathol., 2003, 43, 254-62.
61. Sinisi, A.A.; Chieffi, P.; Pasquali, D.; Kisslinger, A.; Staibano, S.;Bellastella, A.; Tramontano, D. EPN a novel epithelial cell linederived from human prostate tissue. In vitro Cell. Dev. Biol.-An., 2002, 38, 165-72.
62. Picascia A., Stanzione R., Chieffi P., Kisslinger A., Dikic I., Tramontano D. Pyk2 regulates proliferation and differentiation ofprostate cells. Mol. Cell. Endocrinol., 2002, 186, 81-87.
63. Franco, R.; Boscia, F.; Gigantino, V.; Marra, L.; Esposito, F.;Ferrara, D.; Pariante, P.; Caraglia, M.; Minucci, S.; Chieffi, P. GPR30 is over-expressed in post puberal testicular germ celltumors. Cancer Biol. Ther., 2011, 11, 609-13.
64. Vitale, G; Dicitore, A.; Sciortino, G.; Abbruzzese, A.; Persani, L.;Santini, D. Role of GPR30 in testicular germ cell tumors: apotential new anticancer target. Cancer Biol. Ther., 2011, 11, 733-5.
65. Bernstein, E.; Kim, S.Y.; Carmell, M.A.; Murchison, E.P.; Alcorn, H., Li, M.Z.; Mills, A.A.; Elledge, S.J.; Anderson, K.V.; Hannon, G.J. Dicer is essential for mouse development. Nat. Genet., 2003, 35, 215-7.
66. Voorhoeve, P.M.; le Sage, C.; Schrier, M.; Gillis, A.J.; Stoop, H.;Nagel, R.; Liu, Y.P.; van Duijse, J.; Drost, J.; Griekspoor, A.;Zlotorynski, E.; Yabuta, N.; De Vita, G.; Nojima, H.; Looijenga, L.H.; Agami, R. A genetic screen implicates miRNA-372 andmiRNA-373 as oncogenes in testicular germ cell tumors. Cell, 2006, 12, 1169-81.
67. Carmena, M.; Earnshaw, W.C.; The cellular geography of aurorakinases. Nat. Rev. Mol. Cell Biol., 2003 4, 842-54.
68. Portella G., Passaro C., Chieffi P. Aurora B: a new prognosticmarker and therapeutic target in cancer. Curr. Med. Chem., 2011, 18, 482-96.
69. Mayer, F.; Stoop, H.; Sen, S.; Bokemeyer, C.; Oosterhuis, J.W.;Looijenga, L.H.J. Aneuploidy of human testicular germ cell tumorsis associated with amplification of centrosomes. Oncogene, 2003, 22, 3859-66.
70. Katayama, H.; Brinkley, W.R.; Sen, S. The Aurora kinases: role incell transformation and tumorigenesis. Cancer Metastasis Rev., 2003, 22, 451-64.
71. Chieffi, P.; Franco, R.; Fulgione, D.; Staibano S. PCNA in thetestis of the frog, Rana esculenta: a molecular marker of the mitotictesticular epithelium proliferation. Gen. Comp. Endocrinol., 2000, 119, 11-6.
72. Krause, D.S.; Van Etten, R.A. Tyrosine kinases as targets forcancer therapy. N. Engl. J. Med., 2005, 353, 172-87.
73. Kemmer, K.; Corless, C.L.; Fletcher, J.A.; McGreevey, L.; Haley, A.; Griffith, D.; Cummings, O.W.; Wait, C.; Town, A. Heinrich, M.C. KIT mutations are common in testicular seminomas. Am. J. Pathol., 2004, 164, 305-13.
74. Palumbo, C.; van Roozendaal, K.; Gillis, A.J.; van Gurp, R.H.; de Munnik, H.; Oosterhuis, J.W.; van Zoelen, E.J.; Looijenga, L.H. Expression of the PDGF alpha-receptor 1.5 kb transcript, OCT-4, and c-KIT in human normal and malignant tissues Implications forthe early diagnosis of testicular germ cell tumours and for ourunderstanding of regulatory mechanisms. J. Pathol., 2002, 196, 467-77.
75. Manova, K.; Nocka, K.; Besmer, P.; Bachvarova, R.F. Gonadalexpression of c-kit encoded at the W locus of the mouse. Development, 1990, 110, 1057-69.
76. Looijenga, L.H.; de Leeuw, H.; van Oorschot, M.; van Gurp, R.J.;Stoop, H.; Gillis, A.J.; de Gouveia Brazao CA, Weber RF, KirkelsWJ, van Dijk T, von Lindern M, Valk P, Lajos G, Olah E, NeslandJM, Fosså SD, Oosterhuis JW. Stem cell factor receptor (c-KIT)codon 816 mutations predict development of bilateral testiculargerm-cell tumors. Cancer Res., 2003, 63, 7674-8.
77. Heinrich, M.C.; Blanke, C.D.; Druker, B.J.; Corless, C.L. Inhibition of KIT tyrosine kinase activity: a novel molecularapproach to the treatment of KIT-positive malignancies. J. Clin. Oncol., 2002, 20, 1692-703.
78. Folkman, J. New perspectives in clinical oncology fromangiogenesis research. Eur. J. Cancer, 1996, 32, 2534-9.
79. Ferrara, N. Vascular endothelial growth factor: basic science andclinical progress. Endocr. Rev., 2004, 25, 581-611.
80. Gasparini, G.; Longo, R.; Toi, M.; Ferrara, N. Angiogenicinhibitors: a new therapeutic strategy in oncology. Nat. Clin. Pract. Oncol., 2005, 2, 562-77.
81. Ranieri, G.; Patruno, R.; Ruggirei, E.; Montemurro, S.; Valerio, P.;Ribatti, D. Vascular endothelial growth factor (VEGF) as a targetof bevacizumab in cancer: from the biology to the clinic. Curr. Med. Chem., 2006, 1, 1845-7.
82. Zakarija, A.; Soff, G. Update on angiogenesis inhibitors. Curr. Opin. Oncol., 2005, 6, 578-83.
83. Lee, D. Phase II data with ZD6474, a small-molecule kinaseinhibitor of epidermal growth factor receptor and vascularendothelial growth factor receptor, in previously treated advancednon-small-cell lung cancer. Clin. Lung Cancer, 2005, 7, 89-91.